Reactivity against microsatellite instability-induced frameshift mutations in patients with inflammatory bowel disease

World J Gastroenterol. 2015 Jan 7;21(1):221-8. doi: 10.3748/wjg.v21.i1.221.

Abstract

Aim: To analyze the cellular immune response towards microsatellite-instability (MSI)-induced frameshift-peptides (FSPs) in patients suffering from inflammatory bowel disease (IBD) with and without thiopurine-based immunosuppressive treatment.

Methods: Frequencies of peripheral blood T cell responses of IBD patients (n = 75) against FSPs derived from 14 microsatellite-containing candidate genes were quantified by interferon-γ enzyme-linked immunospot. T cells derived from 20 healthy individuals served as controls.

Results: Significant T cell reactivities against MSI-induced FSPs were observed in 59 of 75 IBD patients (78.7%). This was significantly more as we could observe in 20 healthy controls (P = 0.001). Overall, the reactivity was significantly influenced by thiopurine treatment (P = 0.032) and duration of disease (P = 0.002) but not by duration or cumulative amount of thiopurine therapy (P = 0.476). Unexpected, 15 of 24 (62.5%) IBD patients without prior thiopurine treatment also showed increased FSP-specific immune responses (P = 0.001).

Conclusion: These findings propose FSPs as potential novel class of inflammation-associated antigens and this in turn may have implications for screening, diagnosis as well as clinical management of patients suffering from IBD and other inflammatory conditions.

Keywords: Frameshift peptides; Immune response; Inflammatory bowel diseas; Microsatellite-instability; Thiopurine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Autoantigens / genetics*
  • Autoantigens / immunology
  • Case-Control Studies
  • Female
  • Frameshift Mutation*
  • Genetic Markers
  • Genetic Predisposition to Disease
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Inflammatory Bowel Diseases / drug therapy
  • Inflammatory Bowel Diseases / genetics*
  • Inflammatory Bowel Diseases / immunology
  • Male
  • Mercaptopurine / analogs & derivatives
  • Mercaptopurine / therapeutic use
  • Microsatellite Instability*
  • Middle Aged
  • Phenotype
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology
  • Time Factors
  • Treatment Outcome
  • Young Adult

Substances

  • Autoantigens
  • Genetic Markers
  • Immunosuppressive Agents
  • azathiopurine
  • Mercaptopurine